Early in solid tumor development, antigens are presented in tumor-draining lymph nodes
(tdLNs), a process that is necessary to set up immune surveillance. Recent evidence …

Immunotherapy has made significant strides in cancer treatment, particularly through
immune checkpoint blockade (ICB), which has shown notable clinical benefits across …

Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising
cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most …

Chemoimmunotherapy is an emerging paradigm in the clinic for treating several malignant
diseases, such as non-small cell lung cancer, breast cancer, and large B-cell lymphoma …

CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of
various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity …

ARID1A deletion mutation contributes to improved treatment of several malignancies with
immune checkpoint inhibitors (ICIs). However, its role in modulating of tumor immune …

Background Melanoma, the most lethal form of skin cancer, has undergone a transformative
treatment shift with the advent of checkpoint blockade immunotherapy (CBI). Understanding …

Immune cells that infiltrate the tumor microenvironment (TME) play crucial roles in shaping
cancer development and influencing clinical outcomes and therapeutic responses …

Immune checkpoint molecules are a group of molecules expressed on the surface of
immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor …

The insufficient abundance and weak activity of tumour-infiltrating lymphocytes (TILs) are
two important reasons for the poor efficacy of PD-1 inhibitors in hepatocellular carcinoma …